Cited 0 times in
당뇨병 주사제: Glucagon-Like Peptide-1 수용체작용제
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강은석 | - |
dc.contributor.author | 이인국 | - |
dc.date.accessioned | 2019-12-18T00:55:35Z | - |
dc.date.available | 2019-12-18T00:55:35Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 2233-7431 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173278 | - |
dc.description.abstract | According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP- 1 RA) is recommended in diabetic patients with established atherosclerotic cardiovascular disease. This recommendation is based on the results of recent cardiovascular outcome trials of this kind of medications. GLP-1 RAs have a glucose lowering effect with weight loss and a lower incidence of hypoglycemia, and can improve cardiovascular outcomes such as three-point major cardiovascular events composed of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke. Also, several GLP-1 RAs have beneficial effects on renal outcomes, mainly due to improvement in macroalbuminuria. In addition, high-dose liraglutide (3 mg/day subcutaneous injection) showed efficacy for reducing body weight. Therefore GLP-1 RA may be effective in patients with established cardiovascular disease, chronic kidney disease, and/or metabolic syndrome. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | Korean Diabetes Association | - |
dc.relation.isPartOf | Journal of Korean Diabetes | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 당뇨병 주사제: Glucagon-Like Peptide-1 수용체작용제 | - |
dc.title.alternative | Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | 이인국 | - |
dc.contributor.googleauthor | 강은석 | - |
dc.identifier.doi | 10.4093/jkd.2019.20.3.149 | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A05798 | - |
dc.relation.journalcode | J02878 | - |
dc.subject.keyword | Cardiovascular diseases | - |
dc.subject.keyword | Diabetes mellitus | - |
dc.subject.keyword | Glucagon-like peptide-1 | - |
dc.subject.keyword | Kidney diseases | - |
dc.subject.keyword | Obesity | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | 강은석 | - |
dc.contributor.affiliatedAuthor | 이인국 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 149 | - |
dc.citation.endPage | 156 | - |
dc.identifier.bibliographicCitation | Journal of Korean Diabetes, Vol.20(3) : 149-156, 2019 | - |
dc.identifier.rimsid | 64617 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.